Misplaced Pages

#837162

16-618: The 2022–2025 executive committee of the IUIS is Miriam Merad , President; Rita Carsetti, Vice-President; João P. B. Viola, Secretary General; Michael Ratcliffe, Treasurer; Faith Osier , Past President. Every three years the IUIS organizes an international congress, called the International Congress of Immunology (ICI), with one of its national society members. The ICI congress (rebranded as IUIS2019) took place in Beijing, China, in 2019. IUIS2023

32-635: A PhD in the laboratory of Edgar Engleman. Merad’s clinical training in Hematology / Oncology and bone marrow transplantation in the Hôpital Saint-Louis and Institut Gustave Roussy in Paris shaped her initial interest in immunotherapy and inspired her move to Stanford to study dendritic cell-based vaccines with Engleman. Realizing that very little was known about myeloid cell development, Merad collaborated with Irving Weissman at Stanford, who provided her with

48-737: A member of the United States National Academy of Sciences and the National Academy of Medicine . Miriam Merad received her M.D. from the medical school at the University of Algiers in 1985 and completed her residency in hematology and oncology at the Paris Diderot University . After obtaining a Master's degree in Biotechnology from the Paris Diderot University , she moved to Stanford University to perform

64-581: A new subset of dendritic cells, the tissue resident CD103+ DC lineage, that are specialized in anti-viral and anti-tumor immunity. Understanding how different myeloid cell subsets drive distinct inflammatory diseases is one focus of the Merad group's research. In 2021, they identified how mutations in mitogen-activated protein kinase pathway genes trigger sensescence in multipotent human hematopoietic progenitor cells that cause multisystem Langerhans Cell Histiocytosis disease by skewing progenitor differentiation towards

80-748: Is a stub . You can help Misplaced Pages by expanding it . Miriam Merad Miram Merad (born 1969) is a French-Algerian professor in Cancer immunology and the Director of the Marc and Jennifer Lipschultz Precision Immunology Institute (PrIISM) at the Icahn School of Medicine at Mount Sinai (ISMMS) in New York, NY. She is the corecipient of the 2018 William B. Coley Award for Distinguished Research in Basic Immunology and

96-521: Is classification of primary immunodeficiency diseases . Immunohub is IUIS official education platform which hosts and restores all the educational content, including and not limited to IUIS Congresses recordings, Day of Immunology webinar, Women in Science webinar, and etc. Immunopaedia is one of the educational provider of online pre-course material for IUIS immunology courses in the developing world and in other countries. This immunology article

112-714: The Human Immune Monitoring Center, the Microbiome Translational Center, the Center for Inborn Errors of Immunity, the TARGET and INTERACT programs and the Center for Computational Immunology. In August 2023, Merad became the founding Chair of the Department of Immunology and Immunotherapy (DII), a new research department launched at Icahn Mount Sinai that intends to foster a comprehensive understanding of

128-403: The different developmental origins dictating their specific roles in shaping the tumor microenvironment. In human lung tumors, Merad's team found that tissue-resident macrophages gather near to tumour cells early in tumour formation and make the tumour cells more invasive, and they also activate a regulatory T cell response that protects the tumour cells from the immune system. During tumor growth,

144-582: The first to identify the mechanisms that control the development and functional identity of tissue resident dendritic cells and macrophages . In particular, her laboratory established the embryonic origin of tissue resident macrophages , microglia and Langerhans cells and investigates their distinct contributions to health and disease. These studies have revealed the critical contribution of tissue resident macrophages to organ physiology including synaptic pruning, gut peristaltism, fat metabolism and vascular integrity. The Merad laboratory identified

160-495: The fundamental biology and profound impact of the immune system on human health and disease. The DII aims to empower researchers to explore groundbreaking scientific inquiries about the immune system and develop innovative types of immunotherapy. In April 2024, Merad was named as the new Dean for Translational Research and Therapeutic Innovation for the Ican School of Medicine at Mount Sinai . Miram Merad's early studies were among

176-509: The mononuclear phagocyte lineage. In 2022, they reported that severe COVID19 disease was associated with a reduction in the tissue-resident lung alveolar macrophages that control tissue repair and an increase in inflammatory monocytes and monocyte-derived macrophages. The Merad lab has made many discoveries demonstrating the roles that dendritic cells and macrophages play within the tumor microenvironment . The two distinct lineages of macrophages that Merad defined are represented in tumors, with

SECTION 10

#1732859131838

192-454: The niches in tumors in which mregDCs operate. The Merad lab generates detailed transcriptional and epigenetic atlases of dendritic cells and macrophages that are available as resources to uncover new insights into the regulatory networks and molecular identity of these myeloid cells. In addition to her research program, Merad has published articles on new approaches to cancer immunotherapy clinical trials, how Long COVID can be classified,

208-515: The tissue-resident macrophages move to the periphery and monocyte-derived macrophages dominate the tumor-microenvironment. Other recent key advances from the Merad team in this area include the identification of TREM2 tumor macrophages as immunosuppressive cells that limit natural killer cell recruitment and activity in a murine model of lung adenocarcinoma, the characterization of mature dendritic cells enriched in immunoregulatory molecules (mregDCs) that limit responses to immune checkpoint blockade, and

224-580: The tools to study the origin of macrophages and dendritic cells. Merad's collaboration with Weissman resulted in a series of ontogeny studies that led to the re-writing of textbook chapters describing the origin of macrophages and dendritic cells. She was first recruited to the ISMMS in 2004 and promoted to the rank of associate professor with Tenure in 2007 and to Full Professor in 2010. She obtained an Endowed Chair in Cancer Immunology in 2014. In 2016, Merad

240-910: Was appointed Director of the Immunology Institute at ISMMS, which had been founded by Lloyd Mayer and Sergio A. Lira in 2007. The institute was renamed the Precision Immunology Institute (PrIISM) to reflect Merad's vision of transforming the institute to encompass a new, dedicated focus on human immunology and accelerating the translation of research advances made in foundational immunology in preclinical models into new therapeutic approaches. Under Merad's leadership, PrIISM has launched and co-founded with other ISMMS institutes, many programs and centers that support highly productive collaborations between physicians and scientists and enhance synergy between fundamental, translational and clinical research initiatives. These centers and programs include

256-504: Was held in Cape Town, South Africa. Vienna, Austria will host IUIS2025. Frontiers in Immunology is the IUIS' official journal. The standing committees of the IUIS are Clinical Immunology, Early Career, Education, Gender Equity, Inborn Errors of Immunity , Immunotherapy, Nomenclature, Publications, Quality Assessment and Standardization, Vaccines, and Veterinary. Among their activities

#837162